

Form 604
Corporations Act 2001
Section 671B

Notice of change of interests of substantial holder

To Company/registered scheme/notified foreign passport fund name	Radiopharm Theranostics Limited (ASX:RAD)
ACN/ARSN/APFRN	647 877 889
NFPFRN (if applicable)	N/A
1. Details of substantial holder (1)	
Name	This notice is given by Lantheus Omega, LLC (Lantheus), Lantheus Holdings, Inc. CIK 0001521036 (LHI) and each of the entities listed in Annexure 'A' (LHI Subsidiaries)
ACN/ARSN/APFRN (if applicable)	N/A
NFPFRN (if applicable)	N/A

There was a change in the interests of the substantial holder on 09/12/2025

The previous notice was given to the company, or the responsible entity for a registered scheme, or the operator of a notified foreign passport fund on 22/01/2025

The previous notice was dated 21/01/2025

2. Previous and present voting power

The total number of votes attached to all the voting shares or interests in the company, scheme or fund that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company, scheme or fund, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Fully paid ordinary shares in RAD (RAD Shares)	282,958,513	12.12%	537,958,513	15.18%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company, scheme or fund, since the substantial holder was last required to give a substantial holding notice to the company, scheme or fund are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
09/12/2025	Lantheus	Increase of relevant interest in RAD Shares under s 608(1)(a) of the Corporations Act 2001 (Cth) (Corporations Act) as a result of the issue of new RAD Shares following a placement by RAD of such shares to Lantheus under a Share Subscription Agreement entered into between Lantheus and RAD dated 15 October 2025, a copy of which is set out as Annexure 'B' of 10 pages (Subscription Agreement)	A\$0.03 per RAD Share in accordance with the Subscription Agreement	255,000,000 RAD Shares	255,000,000
09/12/2025	LHI	Relevant interests under s 608(3)(b) of the Corporations Act as it controls Lantheus	A\$0.03 per RAD Share in accordance with the Subscription Agreement	255,000,000 RAD Shares	255,000,000

09/12/2025	LHI Subsidiaries (excluding Lantheus and LHI)	Deemed relevant interest under s 608(3)(a) of the Corporations Act	A\$0.03 per RAD Share in accordance with the Subscription Agreement	255,000,000 RAD Shares	255,000,000
------------	---	--	---	------------------------	-------------

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
Lantheus	Lantheus	Lantheus	Lantheus' relevant interest Arises under s 608(1)(a) of the Corporations Act as the registered holder of the existing and new RAD Shares	537,958,513 RAD Shares	537,958,513
LHI	Lantheus	Lantheus	Relevant interests under s 608(3)(b) of the Corporations Act as it controls Lantheus	537,958,513 RAD Shares	537,958,513
LHI Subsidiaries (excluding Lantheus and LHI)	Lantheus	Lantheus	Deemed relevant interest Under s 608(3)(a) of the Corporations Act	537,958,513 RAD Shares	537,958,513

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting securities in the company, scheme or fund are as follows:


Name and ACN/ARSN/APFRN (if applicable) and NFPFRN (if applicable)	Nature of association
N/A	N/A

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Each person described in paragraph 3 above	201 Burlington Road, South Building, Bedford, MA, 01730

Signature

print name	Daniel Niedzwiecki	capacity	General Counsel
sign here		date	06/01/2026

DIRECTIONS

(1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.


- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
 - (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
 - (4) The voting shares of a company constitute one class unless divided into separate classes.
 - (5) The person's votes divided by the total votes in the body corporate, scheme or fund multiplied by 100.
 - (6) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
 - (7) Details of the consideration must include any and all benefits, money or otherwise, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
 - (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
 - (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
-

ANNEXURE 'A'

LHI Subsidiaries

This is Annexure 'A' of 2 pages referred to in the Form 604 (Notice of change of interests of substantial holder) in relation to Radiopharm Theranostics Limited ACN 647 877 889

DocuSigned by:

5DDEEB72DBC4A41...
Daniel Niedzwiecki
General Counsel

Date: 6 January 2026

Details of Subsidiary	Address	Country of Incorporation	Beneficial Interest
Lantheus Medical Imaging, Inc.	201 Burlington Road, South Building, Bedford, MA 01730	USA	LHI is the 100% ultimate beneficial owner of all subsidiaries listed
Aphelion LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Lantheus Five, LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Lantheus One, LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Meilleur Technologies, Inc.	308 North Peters Road, Suite 201, Knoxville, TN 37922	USA	
Lantheus Omega, LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Lantheus Alpha Therapy, LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Lantheus MI Canada, Inc.	1111 Dr. Frederik-Philips Blvd., Suite 600 Montreal, Quebec, H4m 2x6, Canada	Canada	
Lantheus Radiopharmaceuticals UK Limited	Ashcombe Court, Woolsack Way, Godalming, Surrey, United Kingdom, GU7 1LQ	England and Wales	
Lantheus MI UK Limited	Ashcombe Court, Woolsack Way, Godalming, Surrey, United Kingdom, GU7 1LQ	England and Wales	
Lantheus EU Limited	Rocktwist House, Block 1, Western Business Park, Shannon, Co. Clare, V14 FW97, Ireland	Ireland	
Lantheus MI Real Estate, LLC	331 Treble Cove Road, North Billerica, MA 01862	USA	
Progenics Pharmaceuticals, Inc	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Lantheus Two, LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Cerveau Technologies, Inc.	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Lantheus Three, LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
EXINI Diagnostics AB	Ideon Science Park, Scheelevagen 27, 223 70 Lund, Sweden	Sweden	
MNTX Royalties Sub LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
PSMA Development Company LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Progenics Pharmaceuticals Nevada, LLC	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Molecular Insight Pharmaceuticals, Inc.	201 Burlington Road, South Building, Bedford, MA 01730	USA	
Excelsior Life Sciences Ireland Limited	25/28 North Wall Quay, Dublin D01 H104, Ireland	Ireland	


Lantheus Switzerland GmbH	Steinentorstrasse 18 4051 Basel, Switzerland	Germany	
Life Molecular Imaging Ltd.	25 Barnes Wallis Road,, Fareham, Hampshire, United Kingdom, PO15 5TT	England and Wales	
Life Molecular Imaging GmbH	Tegeler Str. 6-7, 13353 Berlin, Germany	Germany	
Evergreen Theragnostics Inc.	27 Commerce Street, Springfield, NJ 07081	USA	
Evergreen Discovery LLC	27 Commerce Street, Springfield, NJ 07081	USA	
27 Commerce Street LLC	27 Commerce Street, Springfield, NJ 07081	USA	

ANNEXURE 'B'

Subscription Agreement

This is Annexure 'B' of 11 pages referred to in the Form 604 (Notice of change of interests of substantial holder) in relation to Radiopharm Theranostics Limited ACN 647 877 889

I certify that the Subscription Agreement in Annexure B is a true copy of the original Subscription Agreement.

DocuSigned by:

5DDEEB72DBCA4A1...
Daniel Niedzwiecki
General Counsel

Date: 6 January 2026

Execution Copy

Strictly Private & Confidential

October 15, 2025

Urgent - acceptance required by
6:00 am on October 16, 2025 (Boston time)

SUBSCRIPTION AGREEMENT

Private Placement of Ordinary Shares of Radiopharm Theranostics Limited

Lantheus Omega, LLC
201 Burlington Road
Bedford, MA 01739
USA

1. Introduction

Radiopharm Theranostics Limited, an Australian company (the "Company") listed on the Australian Securities Exchange ("ASX") and Nasdaq, is pleased to invite Lantheus Omega, LLC ("you"), a wholly-owned subsidiary of Lantheus Holdings, Inc., to participate in a private placement (the "Placement") of US\$5 million of new fully paid ordinary shares in the Company (the "New Shares") with one free attaching option for each New Share subscribed for under the Placement (the "New Options") to be issued on the same terms as the Placement, at the Placement price.

The New Shares will be issued subject to shareholder approval in respect of ASX Listing Rule 7.1 and/or Listing Rule 7.1A (in accordance with Listing Rule 7.3 and Listing Rule 7.3A) and will, if approved, be issued upon receipt of such approval and payment by you.

2. Offer

You are offered to participate in the Placement, subject to the terms set out below in this Agreement. Please complete and return the Confirmation Letter, attached as Annexure A, by 6:00 am (Boston time) on October 16, 2025.

Your payment in respect of the New Shares allocated to you is to be made in clear funds to the account specified in paragraph 15 of this Agreement and must be received by the Company by no later than the closing date set in respect of the Placement (**Closing Date**). Share allotment will be made within seven days of receiving the cleared funds.

To facilitate settlement of your allotment of New Shares, please also complete and return the Registration Details in Annexure A to the Company at your earliest convenience and in any event by no later than the Closing Date .

The Company shall issue the New Shares to you on the Closing Date subject to the conditions set out in paragraph 4 below, including receipt of your payment in respect of the New Shares in clear funds.

3. Use of Proceeds

The Company intends to use the net proceeds from the Placement to support its clinical trial pipeline and otherwise for general working capital for the Company.

4. Conditions of the Placement

If the Company does not receive payment in accordance with this Agreement, then the Company may, at its discretion, terminate this Agreement by written notice to you, without prejudice to its other rights and remedies.

5. Rights Attaching to the New Shares

Upon their issuance, the New Shares will rank *pari passu* in all respects with the existing ordinary shares in the Company.

6. Offer Personal

The offer of New Shares to you on the terms and conditions set out in this Agreement and the agreement arising from your acceptance of the offer is personal to you and (other than by nominating an associated entity to be the recipient of the New Shares in the Registration Details, in which case any reference to “you” or “your” in this Agreement includes that nominated associated entity) you may not prior to settlement of the Placement assign, transfer, or in any other manner, deal with the New Shares, or your rights or obligations under this Agreement, without the prior written agreement of the Company.

7. Acceptance Binding

You agree to be bound by this Agreement, as evidenced by your execution of the Confirmation Letter, notwithstanding any changes to the anticipated timetable.

8. Restricted Trading of New Shares in the United States

The New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933 or the securities laws of any state and may not be offered or sold except in transactions exempt from, or not subject to, the registration requirements of the Securities Act and any applicable state securities laws.

The New Shares are “restricted securities” as defined in Rule 144(a)(3) under the Securities Act. If you decide to offer, sell, pledge or otherwise transfer all or any part of the New Shares, you acknowledge and agree that they may be offered, sold, pledged or otherwise transferred only:

- (a) to the Company, subject to compliance with applicable laws;
- (b) outside the United States in accordance with Rule 904 of Regulation S under the Securities Act, including in regular brokered transactions on the ASX;
- (c) in accordance with Rule 144A under the Securities Act;
- (d) pursuant to another exemption from registration under the Securities Act; and

- (e) in each case, in compliance with any applicable state securities laws of the United States, after, in the case of proposed transfers under sub-paragraph (d) above, you have furnished to the Company an opinion of counsel of recognized standing or other evidence reasonably satisfactory to the Company to the effect that the proposed transfer may be made without registration under the Securities Act and any applicable state securities laws.

In particular, you will not deposit any New Shares in the Company's American Depositary Receipt program until such time as such shares are no longer "restricted securities" within the meaning of Rule 144(a)(3) of the Securities Act.

9. Representations, Warranties and Agreements of the Purchaser

By accepting this offer of New Shares and New Options (together, the "New Securities"), you represent, warrant, undertake and agree for the benefit of the Company that:

- (a) You are an institutional or corporate accredited investor within the meaning of Rule 501(a)(1), (2), (3), (7), (8), (9) or (12) under the Securities Act;
- (b) You are not acquiring the New Securities with the purpose of selling or transferring the New Securities, or granting, issuing or transferring interests in them in violation of any applicable securities laws.
- (c) You are aware that publicly available information about the Company and its securities can be obtained from the ASX (its website at www.asx.com.au), the US Securities and Exchange Commission (its website at www.sec.gov) and the Company.
- (d) You have had access to all information that you believe is necessary or appropriate in connection with your acquisition of the New Securities.
- (e) You have had an opportunity to ask questions of management of the Company and discuss the Company's business, management and financial affairs with its management.
- (f) You are not subscribing for the New Securities as a result of or subsequent to any advertisement, article, notice or other communication, published in any newspaper, magazine or similar media or broadcast over television, radio, or the internet, or presented at any seminar or meeting, or any solicitation of a subscription by a person not previously known to you in connection with investments in securities generally.
- (g) You have made and relied upon your own assessment of securities of the Company and have conducted your own investigations with respect to the New Securities including, without limitation, the particular tax consequences of acquiring, owning or disposing of the New Securities in light of your particular situation as well as any consequences arising under the laws of any other taxing jurisdiction.
- (h) You understand that the Company may be a "passive foreign investment company" (as defined in section 1297 of the US Internal Revenue Code).
- (i) You have not relied on any investigation that the Company or any persons acting on its behalf may have conducted with respect to the New Securities.

- (j) You acknowledge that this Agreement does not constitute a securities recommendation and that the Company has not had regard to your particular objectives, financial situation and needs.
- (k) You acknowledge that an investment in the New Securities involves a degree of risk.
- (l) You have such knowledge and experience in financial and business matters that you are capable of evaluating the merits and risks of a purchase of the New Securities.
- (m) You have the financial ability to bear the economic risk of the investment in the New Securities.
- (n) You acknowledge that no disclosure document has been prepared in connection with the Placement and the issue of the New Securities.
- (o) You acknowledge that shareholder approval may be required for the issue of the New Securities where such issuance results in you (or any of your “associates”, as that term is defined in the Corporations Act) obtaining a relevant interest in more than 20% of the voting securities of the Company. Your participation will be limited and if necessary, scaled back, such that, on Completion of the Placement, your (together, with your “associates”) voting power will not exceed 19.99%.
- (p) You agree to accept any New Securities issued to you on the terms set out in this Agreement and subject to the Company’s constitution.

10. Representations, Warranties and Agreements of the Company

The Company represents, warrants and covenants as follows:

- (a) **Non-public Material Information.** As soon as possible following the allocation of New Securities in the Placement, the Company will issue a press release regarding the Placement via an announcement to the ASX. After issuance of such press release, the Company warrants that you will not be in possession of any material non-public information respecting the Company by virtue of the execution of this the Confirmation Letter. Further, except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the Company covenants and agrees that neither it, nor any other person acting on its behalf will provide the undersigned or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto the undersigned shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that the undersigned shall be relying on the foregoing covenant in effecting transactions in securities of the Company. In addition, effective upon the filing of the press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company or any of its officers, directors, affiliates, employees or agents, on the one hand, and you or any of your affiliates, on the other hand, shall terminate.
- (b) **Confidentiality.** To the extent that the Company, any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents delivers any material, non-public information to you or any of your affiliates without your consent, the Company agrees that, to the extent permitted by law, you shall not have any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents or any duty not to trade on the basis of such material, non-public information.

- (c) ***Cleansing Notice.*** The New Securities will be in a class of securities listed on the ASX. Upon issuing any of the New Securities, the Company will immediately make application to ASX for official quotation of those New Securities and will lodge with ASX such other documents as are required for those shares to be freely tradeable on ASX without restriction (including issuing a cleansing notice in accordance with section 708A(5)(e) of the Corporations Act which complies with the requirements of section 708A(6) of the Corporations Act ("Cleansing Notice")) within one business day (on which ASX is operating) of being issued. If the Company is unable to issue a Cleansing Notice, it must instead issue and lodge a prospectus in compliance with the requirements of section 708A(11) of the Corporations Act.
- (d) ***Hedging and trading activities.*** The Company understands and acknowledges that you may engage in hedging and/or trading activities at various times during the period that the New Securities are outstanding to the extent such trading and hedging activities are in compliance with all applicable securities, and such hedging and/or trading activities, if any, can reduce the value of the existing security holders' equity interests in the Company both at and after the time the hedging and/or trading activities are being conducted. The Company acknowledges that, to the extent such hedging and/or trading activities are in compliance with all applicable securities laws, they do not constitute a breach of this Agreement.
- (e) ***Disclosure Materials.*** Any document that the Company lodges with the ASX in connection with the Placement, together with all other documents that the Company has previously lodged with ASX, will not as of the date of this Agreement or the settlement date for the Placement, contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
- (f) ***Organization; Qualification.*** The Company is a corporation duly organized, validly existing and, in jurisdictions where such concept is recognized and has all requisite corporate power and authority to own, license, use, lease and operate its assets and properties and to carry on its business as it is now being conducted and as currently proposed by management to be conducted.
- (g) ***Authority.*** The Company has all requisite corporate power and authority to execute and deliver this Agreement and to perform and consummate the transaction contemplated by this Agreement. This Agreement has been duly executed and delivered by the Company and constitute a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights and to general principles of equity.
- (h) ***Consents and Approvals.***
 - (i) The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the actions contemplated herein do not and will not require any filing or registration with, notification to, or authorization, permit, consent or approval of, or other action by or in respect of, any foreign, domestic, state or local governmental body, self-regulatory organization, court, agency, commission, official or regulatory or other authority other than:
 - (A) the regulatory filings referred to herein; and
 - (B) compliance with the rules and regulations of the ASX and the SEC.

- (ii) The execution, delivery and performance by the Company of this Agreement will not:
 - (A) conflict with or result in any breach of any provision of the Company's constitution; or
 - (B) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default under, or give rise to any right of termination, amendment, cancellation or acceleration or the creation or acceleration of any right or obligation under, or result in the creation of any encumbrance upon, any of the properties or assets of the Company under any of the terms, conditions or provisions of any note, bond, mortgage, indenture, loan, credit agreement, lease, license, permit, concession, contract, agreement or other instrument, understanding or obligation, whether written or oral, to which the Company is a party or by which any of its properties or assets may be bound; or
 - (C) violate any judgment, order, writ, preliminary or permanent injunction or decree or any Australian law applicable to the Company, or any of its properties or assets, except in the case of clauses (B) and (C) for violations, breaches, defaults, terminations, amendments, cancellations or accelerations that would not have a material adverse effect on the Company.
- (i) ***Absence of Certain Changes or Events.*** Since its most recent annual report to the date of this Agreement, the business of the Company has been conducted in all material respects in the ordinary course, consistent with past practice and there has been no material adverse change in the financial condition, business, or operations of the Company, except as disclosed in the Company's filings. Without limiting the foregoing, since its most recent annual report to the date of this Agreement, there has not occurred any damage, destruction or loss (whether or not covered by insurance) of any material asset of the Company or any of its subsidiaries which materially affects the use thereof, and the Company has not defaulted on any material agreement to which it is bound.
- (j) ***Litigation.*** Except as disclosed in the Company's public filings, as of the date of this Agreement, there is no suit, claim, action, proceeding or investigation pending before any court, regulatory agency or authority, or governmental agency (each, a "Governmental Authority") or arbitrator or that is, to the knowledge of the Company, threatened by or against the Company that seeks to enjoin any activities of the Company. The Company is not subject to:
 - (i) any outstanding order, writ, judgment, decree or injunction of, or settlement with, any Governmental Authority; or
 - (ii) engaged in any suit, claim, action or proceeding to recover monies due to it or for damages or losses sustained by it that, if the Company failed to collect such monies due it, would have a material adverse effect on it.
- (k) ***Compliance with Applicable Law.*** As at the date of this Agreement, the Company holds all permits, licenses, authorizations, certificates, variances, exemptions, orders and approvals of all governmental authorities necessary for the lawful conduct of its business as presently conducted and to its assets and properties except for failures to hold any such permits that would not have a material adverse effect on the Company.

- (l) **Taxes.** Except as disclosed in its publicly filed documents, as at the date of this Agreement, the Company has filed, or has caused to be filed on its behalf, all material Australian and other foreign returns, estimates, declarations, information statements and reports relating to taxes ("Returns") required to be filed by the Company with any tax authority, and such Returns are true and correct in all material respects. The Company and each of its subsidiaries have paid all material taxes shown on such Returns that are due.
- (m) **Insurance.** As at the date of this Agreement, the Company maintains all policies of insurance that are required by applicable law and contracts relating to the Company. The insurance policies, to the knowledge of the Company:
 - (i) have been issued by insurers which are reputable and financially sound;
 - (ii) provide coverage for the operations conducted by the Company of a scope and coverage which the directors of the Company believe to be adequate; and
 - (iii) are in full force and effect.
- (n) **Disclosure.** As at the date of this Agreement, there has been no material failure by the Company to comply with its periodic disclosure obligations (except as announced to ASX) and continuous disclosure obligations under the ASX Listing Rules and the Corporations Act.

11. Governing Law and Jurisdiction

This Agreement between the Company and you arising out of your acceptance of the terms of this offer shall be governed by the laws of the State of Victoria. Both parties agree that all disputes arising hereunder shall be submitted to courts sitting in Victoria.

12. Entire Agreement

Subject to this paragraph, upon acceptance of the offer by you the terms contained in this Agreement including, without limitation the Confirmation Letter and Registration Details (Annexure A), constitute the entire agreement between the Company and you as to the Placement to the exclusion of all prior representations, understandings and agreements between the Company and you. Any variation of the terms of this Agreement must be in writing signed by the Company and you. However, the foregoing does not affect the enforceability of your commitment not to withdraw or amend your acceptance of the offer of New Securities and to be bound to subscribe for New Securities allocated to you.

13. Notices

Any notice to be given relating to the offer of New Securities or your acceptance of the Placement may be sent electronically to the fax number or e-mail address of the party to whom the notice is sent (as notified to the other party in writing) and will be deemed to have been given upon the successful transmission to the applicable e-mail address so long as an automatically generate message of delivery failure is not received by the sender.

In addition, any notice and service of process shall be deemed to have been duly given upon receipt if personally delivered, sent by overnight courier or mailed:

- (a) if to the Investor, addressed to investor at the address set forth in the attached Confirmation Letter

Execution Copy

(b) if to the Company, addressed to:

Radiopharm Theranostics Limited
Attention: Phillip Hains, Director and Company Secretary
Level 3, 62 Lygon Street
Carlton, VIC 3053
Australia
email: rc@radiopharmtheranostics.com

14. Confirmation Letter and Registration Details


In order to confirm your participation in the Placement, you must execute and deliver a fully completed Confirmation Letter (in the form attached in Annexure A), which incorporates by reference the representations, warranties, undertakings and agreements set out in this Agreement. The executed Confirmation Letter is taken to be an application to subscribe (if relevant on behalf of your settlement nominee) for the New Securities.

In order to facilitate the registration of the New Securities, and as a condition of the issue of the New Securities, you agree to complete and return the Registration Details in Annexure A.

15. Settlement

You will be required to make full payment for your allocation of the New Shares to:

Bank:
Account Number:
Account Name:
Swift:
Bank address:
Reference:



Any questions relating to settlement should be directed to Phillip Hains, Company Secretary of the Company, at email Phillip.Hains@acclime.com or by telephone on +61 408 579 121.

Yours faithfully,

Executed by Radiopharm Theranostics Limited

A handwritten signature in black ink, appearing to read 'Riccardo Canevari', written over a horizontal line.

Riccardo Canevari
Director and Chief Executive Officer

Execution Copy

Annexure A

Confirmation Letter

Reply to: Riccardo Canevari, CEO, Radiopharm Theranostics Limited
Email: rc@radiopharmtheranostics.com

Commitment to acquire Ordinary Shares

We refer to the Subscription Agreement, dated October 15, 2025, with Radiopharm Theranostics Limited.

We confirm our irrevocable and unconditional undertaking to subscribe for our allocation upon the terms and conditions set out in the Agreement:

	Total Subscription Amount in US\$
Allocation	US\$5,000,000

In connection with our participation as set out above, the undersigned hereby confirms (for the benefit of the Radiopharm Theranostics Limited) the various representations, warranties and agreements contained in the Subscription Agreement.

Please note the following details:

Investor (full legal name): Lantheus Omega, LLC.....

Contact Name: Daniel Niedzwiecki.....

Address: 201 Burlington Road, South Building, Bedford, MA 01730.....

Email: daniel.niedzwiecki@lantheus.com.....

Phone: 978-671-8648.....

Details of Authorized Signatory

Signature:  Date: October 15, 2025
DocuSigned by: 625F813A88B24C3...

Name: Brian Markison.....

Title: CEO.....

***This Confirmation Letter must be emailed to rc@radiopharmtheranostics.com
by no later than 6:00 am (Boston time) October 16, 2025***

Execution Copy

Registration Details

Subject to terms and conditions of the Subscription Agreement, the Investor named in the Confirmation Letter directs Radiopharm Theranostics Limited to register the allocated Shares as follows:

(Please complete the following information for settlement using more copies of this form for separate fund & payments).

Australian agent details (if any)

Agent Name: _____

Agent Bic Code: _____

Agent Chess account: _____

Account name of beneficiary: Lantheus Omega LLC

Account number of beneficiary: _____

Bic code of beneficiary: _____

Investor contact for payments Phone 1-978-436-7884

(include country & area codes)

Email stacy.donohoe@lantheus.com

Investor contact for Settlement Phone 1-978-436-7884

(include country & area codes)

Email stacy.donohoe@lantheus.com

Settlement Contact Details (please provide details of your settlement person's name and contact numbers):

Contact Name: Stacy Donohoe
(Print)

Email: stacy.donohoe@lantheus.com
(Print)

Telephone: 1-978-436-7884 Facsimile: _____
(include country & area codes)

All settlement enquiries are to be directed to to Phillip Hains, Company Secretary of the Company, at email Phillip.Hains@acclime.com or by telephone on +61 408 579 121.